A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
Stopped Recruitment challenges: competition with another microbiome trial, patient refusal to join a dietary intervention study, poor tolerance of oral DPD (Grade 2 mucositis), and issues with organizing biological sample collection.
Conditions
- Metastatic Renal Cell Carcinoma
Interventions
- DIETARY_SUPPLEMENT: Continuous ketogenic diet
- DIETARY_SUPPLEMENT: Discontinuous ketogenic diet
- DIETARY_SUPPLEMENT: beta-hydroxybutyrate (BHB) supplementation
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris